Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | PKLR | P30613 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17100632 | 0.91 | PKM (0.56) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17100757 | 0.90 | GBA1 (0.52) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17100640 | 0.90 | LMNA (0.52) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17100767 | 0.89 | CCR6 (0.49) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17100842 | 0.88 | ALDH1A1 (0.59) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17100954 | 0.88 | PKM (0.56) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17101010 | 0.86 | PKM (0.56) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17100814 | 0.85 | HSD11B1 (0.47) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17115045 | 0.84 | PKM (0.57) | PKMLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL17100597 | 0.83 | PKM (0.56) | PKMLMNAALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | claimed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | claimed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562869-B2 | Oxadiazole compounds | OXA1L, PSEN1, MAPT | PKM 362/4885LMNA 760/4885ALDH1A1 482/4885 |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | PKM 354/4885LMNA 748/4885ALDH1A1 561/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | PKM 362/4885LMNA 760/4885ALDH1A1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.